Skip to main content
Equibles
DFTX logo

DFTX · Definium Therapeutics, Inc.

Track DFTX — free

Use DFTX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about DFTX

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$42.63 -1.27 (-2.89%) At close · Aug 14
Market Cap
$5.73B
Shares
134.37M

Definium Therapeutics, Inc. Earnings Call Transcripts

Every quarterly earnings call for Definium Therapeutics, Inc. (DFTX) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Earnings call
FY26 · Q2
2026-08-06
Q2 2026 Earnings Conference Call
Diluted EPS
$-1.44
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-07
Definium Therapeutics, Inc. Q1 FY2026 Earnings Call
Confident tone DT120 Phase III Program (MDD/GAD) Pipeline Expansion (PTSD, ASD/DT402) Regulatory Progress & DEA Scheduling
Diluted EPS
$-0.71
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Definium Therapeutics, Inc. Q4 FY2025 Earnings Call
Confident tone DT120 ODT Pipeline Progress Major Depressive Disorder Program Generalized Anxiety Disorder Program
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Definium Therapeutics, Inc. Q3 FY2025 Earnings Call
Confident tone Phase III MM120 readouts in GAD and MDD ASCEND second Phase III in MDD MM402 / R-enantiomer of MDMA in autism
Diluted EPS
$-0.78
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-31
Definium Therapeutics, Inc. Q2 FY2025 Earnings Call
Confident tone MM120 ODT Phase III trials Clinical readout timeline Phase IIb efficacy data
Diluted EPS
$-0.50
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Definium Therapeutics, Inc. Q1 FY2025 Earnings Call
Confident tone Disease Burden and Market Opportunity MM120 Phase 3 Program Execution New Chief Commercial Officer Onboarding
Diluted EPS
$-0.35
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-06
Definium Therapeutics, Inc. Q4 FY2024 Earnings Call
Confident tone MM120 Phase 3 GAD Program (Voyage and Panorama) MDD Program (Emerge) Regulatory Designations and IP
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Definium Therapeutics, Inc. Q3 FY2024 Earnings Call
Confident tone MM120 ODT in GAD (Voyage and Panorama Phase 3 studies) MM120 ODT in MDD (Emerge Phase 3 study) Clinical execution and enrollment efficiency
Diluted EPS
$-0.27
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-12
Definium Therapeutics, Inc. Q2 FY2024 Earnings Call
Confident tone MM120 Phase 3 in GAD Expansion into MDD FDA regulatory engagement
Diluted EPS
$-0.26
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Definium Therapeutics, Inc. Q1 FY2024 Earnings Call
Confident tone MM120 Phase IIb results in GAD Pipeline expansion and additional indications ODT formulation and IP
Diluted EPS
$-1.14
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Definium Therapeutics, Inc. Q4 FY2023 Earnings Call
Confident tone MM120 Phase 2b results in GAD Phase 3 development and End-of-Phase 2 meeting MM402 and R(-)-MDMA program in ASD
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Definium Therapeutics, Inc. Q3 FY2023 Earnings Call
Diluted EPS
$-0.45
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Definium Therapeutics, Inc. Q2 FY2023 Earnings Call
Diluted EPS
$-0.76
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Definium Therapeutics, Inc. Q1 FY2023 Earnings Call
Diluted EPS
$-0.65
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-09
Definium Therapeutics, Inc. Q4 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Definium Therapeutics, Inc. Q3 FY2022 Earnings Call
Diluted EPS
$-0.56
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
Definium Therapeutics, Inc. Q2 FY2022 Earnings Call
Diluted EPS
$-0.60
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-16
Definium Therapeutics, Inc. Q1 FY2022 Earnings Call
Diluted EPS
$-0.66
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-28
Definium Therapeutics, Inc. Q4 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–19 of 19 earnings calls
Key facts CIK 1813814 CUSIP 24477V105 13F (30d) 353 filings 350 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)